Glioblastoma is one of the most malignant forms of
cancer, for which no effective targeted
therapy has been found. Although The
Cancer Genome Atlas has provided a list of fusion genes in
glioblastoma, their role in progression of
glioblastoma remains largely unknown. To search for novel fusion genes, we obtained
RNA-seq data from TGS-01 human
glioma-initiating cells, and identified a novel fusion gene (HMGA2-EGFR), encoding a
protein comprising the N-terminal region of the high-mobility group AT-hook
protein 2 (HMGA2) fused to the C-terminal region of
epidermal growth factor receptor (EGFR), which retained the transmembrane and
kinase domains of the EGFR. This fusion gene product showed transforming potential and a high
tumor-forming capacity in cell culture and in vivo. Mechanistically, HMGA2-EGFR constitutively induced a higher level of phosphorylated STAT5B than
EGFRvIII, an in-frame exon deletion product of the EGFR gene that is commonly found in primary
glioblastoma. Forced expression of HMGA2-EGFR enhanced orthotopic
tumor formation of the U87MG human
glioma cell line. Furthermore, the EGFR
kinase inhibitor
erlotinib blocked sphere formation of TGS-01 cells in culture and inhibited
tumor formation in vivo. These findings suggest that, in addition to gene amplification and in-frame exon deletion, EGFR signaling can also be activated by gene fusion, suggesting a possible avenue for treatment of
glioblastoma.